Application Pathways Updated January 14, 2026

What is an NDA?

NDA (New Drug Application) is the FDA submission requesting approval to market a new drug. Learn about NDA requirements, timeline, and the approval process.

Definition

NDA (New Drug Application) is the comprehensive submission through which drug sponsors formally request FDA approval to market a new pharmaceutical product in the United States. The NDA contains all preclinical, clinical, manufacturing, and labeling data demonstrating the drug is safe and effective.

How NDA Works

After completing clinical trials under an IND, sponsors compile all evidence into the NDA submission. FDA reviews the complete package and issues either an Approval Letter or Complete Response Letter.

Key Requirements

  • Preclinical pharmacology and toxicology data
  • Human pharmacokinetics and bioavailability studies
  • Clinical efficacy and safety data from Phase 1-3 trials
  • Chemistry, manufacturing, and controls (CMC) information
  • Proposed labeling and package insert
  • Patent and exclusivity information

NDA Submission Types

TypeDescriptionUse Case
505(b)(1)Full original NDANew molecular entities
505(b)(2)References prior dataModified drugs
RollingSubmitted in sectionsExpedited programs
Paper NDALiterature-basedWell-characterized drugs

NDA Review Timeline

The FDA follows PDUFA timelines for NDA review:

  1. Filing Review: 60 days to accept or refuse to file
  2. Standard Review: 10 months from filing
  3. Priority Review: 6 months from filing
  4. Advisory Committee: Optional expert panel meeting
  5. Decision: Approval Letter or Complete Response Letter

Recent NDA Statistics

In 2024, FDA’s Center for Drug Evaluation and Research (CDER) approved:

  • 55 novel drugs (new molecular entities)
  • 70% received at least one expedited designation
  • Median review time: 10.5 months for standard, 6 months for priority

Why BD Teams Track NDA

For business development professionals, NDA submissions represent key milestones:

  • Deal Implication: NDA filing often triggers milestone payments in licensing deals
  • Due Diligence Focus: Review completeness of the NDA package and FDA interaction history
  • Opportunity Signal: Companies approaching NDA submission often seek commercial partners

Frequently Asked Questions

What is an NDA?

An NDA (New Drug Application) is the formal submission to FDA containing all data needed to demonstrate a drug is safe and effective for its proposed use.

How long does NDA review take?

Standard NDA review takes 10 months; Priority Review takes 6 months. FDA communicates its decision by the PDUFA date.

What is the difference between NDA and IND?

IND authorizes clinical trials in humans; NDA is submitted after trials are complete to request marketing approval for the drug.

What does an NDA contain?

NDAs include preclinical data, clinical trial results, CMC information, proposed labeling, patent information, and any user fee payments.

What are the types of NDA?

There are two main types: 505(b)(1) for full original applications and 505(b)(2) for applications referencing prior FDA findings or published literature.

Track Regulatory Filings with PharmaDB

Get real-time access to FDA approvals, pipeline data, and regulatory intelligence for BD teams.

Join the Waitlist